SEC Form 4 · accession 0001179110-16-017031
AMAG PHARMACEUTICALS INC. · AMAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas Grund
Officer — Chief Commercial Officer
Period of report
Jan 4, 2016
Accepted (ET)
Jan 5, 2016 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000792977
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 4, 2016 | A | 32,000 | — | A | 32,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3 | $28.58 | Jan 4, 2016 | A | 45,000 | A | — | Jan 4, 2026 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1These shares of common stock are issuable pursuant to a grant of restricted stock units that vests in three equal annual installments commencing on January 4, 2017. Each restricted stock unit represents a contingent right to receive one share of AMAG Pharmaceuticals, Inc. common stock.
- F2Not applicable.
- F3This option vests and becomes exercisable in four equal annual installments commencing January 4, 2017.